1. Oh JH, Kwon JG, Jung HK, et al; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29-50. DOI:10.5056/jnm19209
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70-99 [Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99 (in Russian)]. DOI:10.22416/1382-4376-2021-31-4-70-99
3. Ивашкин В.Т., Лапина Т.Л., Маев И.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93 [Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian)]. DOI:10.22416/1382-4376-2022-32-6-72-93
4. Гастрит и дуоденит. Клинические рекомендации. Режим доступа: https://cr.minzdrav.gov.ru/recomend/708_2. Ссылка активна на 30.09.2024 [Gastrit i duodenit. Klinicheskie rekomendatsii. Available at: https://cr.minzdrav.gov.ru/recomend/708_2. Accessed: 30.09.2024 (in Russian)].
5. Яковенко Э.П., Агафонова Н.А., Иванов А.Н., и др. Цитопротектор ребамипид в терапии воспалительных и эрозивно-язвенных поражений желудочно-кишечного тракта. Терапевтический архив. 2016;88(4):88-92 [Yakovenko EP, Agafonova NA, Ivanov AN, et al. The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract. Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(4):88-92 (in Russian)]. DOI:10.17116/terarkh201688488-92
6. Симаненков В.И., Лутаенко Е.А., Никогосян А.А. Клинико-фармакологические особенности применения ребамипида при заболеваниях желудочно-кишечного тракта. Литературный обзор. Медицинский Совет. 2016;(19):88-95 [Simanenkov VI, Lutaenko EA, Nikogosyan AA. Clinical and pharmacological characteristics of the use of rebamipide in diseases of the gastrointestinal tract. Literature review. Medical Council. 2016;(19):88-95 (in Russian)]. DOI:10.21518/2079-701X-2016-19-88-95
7. Симаненков В.И., Тихонов С.В. Ребамипид – новые возможности гастроэнтеропротекции. Терапевтический архив. 2015;87(12):134-7 [Simanenkov VI, Tikhonov SV. Rebamipide: New opportunities of gastroenteroprotection. Terapevticheskii Arkhiv (Ter. Arkh.). 2015;87(12):134-7 (in Russian)]. DOI:10.17116/terarkh20158712134-137
8. Звяглова М.Ю., Князев О.В., Парфенов А.И. Ребамипид: перспективы применения в гастроэнтерологии и не только. Терапевтический архив. 2020;92(2):104-11 [Zvyaglova MYu, Knyazev OV, Parfenov AI. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):104-11 (in Russian)]. DOI:10.26442/00403660.2020.02.000569
9. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022;29(3):72-82 [Trukhan DI, Ivanova DS. Lekarstvennaia bezopasnost' v real'noi klinicheskoi praktike: aktsent na protektornuiu terapiiu. Farmateka. 2022;29(3):72-82 (in Russian)]. DOI:10.18565/pharmateca.2022.3.72-82
10. Лапина Т.Л., Ивашкин В.Т. Ребамипид при хроническом гастрите: эрадикационная терапия H. pylori и восстановление барьерной функции слизистой оболочки желудка. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(6):81-7 [Lapina TL, Ivashkin VT. Rebamipide During Chronic Gastritis: H. pylori Eradication Therapy and Restoration of Gastric Mucosa Barrier Function. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):81-7 (in Russian)].
DOI:10.22416/1382-4376-2023-33-6-81-87
11. Коробейникова Е.Р., Шкатова Е.Ю. Применение ребамипида в комплексной терапии эрозивных поражений гастродуоденальной зоны лиц молодого возраста. Медицинский альманах. 2018;52(1):26-30 [Korobeinikova ER, Shkatova EIu. Primenenie rebamipida v kompleksnoi terapii erozivnykh porazhenii gastroduodenal'noi zony lits molodogo vozrasta. Meditsinskii Al'manakh. 2018;52(1):26-30 (in Russian)].
12. Сагынбаева В.Э., Лазебник Л.Б. Ребамипид – современный гастроцитопротектор при эрозивно-язвенных поражениях верхних отделов желудочно-кишечного тракта: результаты исследования. Терапия. 2019;(8):173-83 [Sagynbaeva VE, Lazebnik LB. Rebamipid – sovremennyi gastrotsitoprotektor pri erozivno-iazvennykh porazheniiakh verkhnikh otdelov zheludochno-kishechnogo trakta: rezul'taty issledovaniia. Terapiia. 2019;(8):173-83 (in Russian)]. DOI:10.18565/therapy.2019.8.173–183
13. Чорбинская С.А., Кудрявцева Н.А., Степанова И.И., и др. НПВП-индуцированное поражение желудочно-кишечного тракта. Новые возможности гастро- и энтеропротекции. Кремлевская медицина. Клинический вестник. 2019;(4):98-104 [Chorbinskaia SA, Kudriavtseva NA, Stepanova II, et al. NPVP-indutsirovannoe porazhenie zheludochno-kishechnogo trakta. Novye vozmozhnosti gastro- i enteroprotektsii. Kremlevskaia meditsina. Klinicheskii vestnik. 2019;(4):98-104 (in Russian)].
14. Мещерякова Г.М., Копылова Д.В., Ватутина В.С. Опыт применения ребамипида в лечении постлучевого колита. Колопроктология. 2019;18(S3):87 [Meshcheriakova GM, Kopylova DV, Vatutina VS. Opyt primeneniia rebamipida v lechenii postluchevogo kolita. Koloproktologiia. 2019;18(S3):87 (in Russian)].
15. Тарасова Л.В., Башкова И.Б., Бусалаева Е.И. НПВП-ассоциированные риски у больных с ревматологическими заболеваниями: анализ врачебных назначений. Экспериментальная и клиническая гастроэнтерология. 2019;9(169):11-6 [Tarasova LV, Bashkova IB, Busalaeva EI. Nsaids-associated risks in patients with rheumatological diseases: analysis of medical prescriptions. Eksperimental'naia i Klinicheskaia Gastroenterologiia. 2019;9(169):11-6 (in Russian)]. DOI:10.31146/1682-8658-ecg-169-9-11-16
16. Бакулина Н.В., Тихонов С.В., Оковитый С.В., и др. Фармакокинетика и фармакодинамика ребамипида. Новые возможности терапии. Терапевтический архив. 2022;94(12):1431-7 [Bakulina NV, Tikhonov SV, Okovityi SV, et al. Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(12):1431-7 (in Russian)]. DOI:10.26442/00403660.2022.12.202000
17. Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. DOI:10.1007/s10620-017-4871-9
18. Lain L. Approaches to nonsteroidal anti-inflammatory drug use in high-risk patient. Gastroenterology. 2001;120(3):594-606. DOI:10.1053/gast.2001.21907
19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-7. DOI:10.1136/bmj.321.7270.1183
20. Cha JM, Kim M, Jo HH, et al. Real-World Risk of Gastrointestinal Bleeding for Direct Oral Anticoagulants and Warfarin Users: A Distributed Network Analysis Using a Common Data Model. Gut Liver. 2024;18(5):814-23. DOI:10.5009/gnl230406
21. Cho KM, Park SY, Chung JO, et al. Risk factors for small bowel bleeding in chronic nonsteroidal anti-inflammatory drug users. J Dig Dis. 2015;16(9):499-504.
DOI:10.1111/1751-2980.12269
22. Kim JE, Lee YC, Kim TS, et al. Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors. Gut Liver. 2024;18(6):1026-36. DOI:10.5009/gnl230372
23. Kim TJ, Kim ER, Hong SN, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696. DOI:10.1038/s41598-019-48173-6
24. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391-8.
DOI:10.7326/0003-4819-149-6-200809160-00005
25. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120-8. DOI:10.1001/jama.2009.722
26. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. DOI:10.1371/journal.pone.0216750
27. Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014;8(4):371-9. DOI:10.5009/gnl.2014.8.4.371
28. Gweon TG, Park JH, Kim BW, et al; Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. DOI:10.5009/gnl17078
29. Парфенов А.И., Белостоцкий Н.И., Хомерики С.Г., и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование. Терапевтический архив. 2019;91(2):25-31 [Parfenov AI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):25-31 (in Russian)]. DOI:10.26442/00403660.2019.02.000123
30. Парфенов А.И., Белостоцкий Н.И., Дбар С.Р., и др. Энтеропатия с нарушением мембранного пищеварения. Эффективная фармакотерапия. 2018;(16):20-7 [Parfenov AI, Belostotsky NI, Dbar SR, et al. Enteropathy with disorder of membrane digestion. Effektivnaia Farmakoterapiia. 2018;(16):20-7 (in Russian)].
31. Бауло Е.В., Белостоцкий Н.И., Ахмадуллина О.В., и др. Влияние диеты FODMAP и ребамипида на активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Терапевтический архив. 2023;95(2):140-4 [Baulo EV, Belostotsky NI, Akhmadullina OV, et al. The effect of the FODMAP and rebamipid diet on the activity of disaccharidases in patients with enteropathy with impaired membrane digestion. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(2):140-4 (in Russian)]. DOI:10.26442/00403660.2023.2.202057
32. Стаценко М.Е., Туркина С.В., Тыщенко И.А., и др. Оценка эффективности ребамипида в лечении функциональной диспепсии и синдрома раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2022;(9):74-81 [Statsenko ME, Turkina SV, Tyshchenko IA, et al. Evaluation of the efficacy of rebamipide in functional dyspepsia and irritable bowel syndrome treatment. Experimental and Clinical Gastroenterology. 2022;(9):74-81 (in Russian)]. DOI:10.31146/1682-8658-ecg-205-9-74-81
33. Song JH, Han YM, Kim WH, et al. Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants. Free Radic Res. 2016;50(10):1071-9. DOI:10.1080/10715762.2016.1181262
34. Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-6. DOI:10.5009/gnl15537
35. Kang DW, Noh YN, Hwang WC, et al. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells. Biochem Pharmacol. 2016;113:36-44. DOI:10.1016/j.bcp.2016.06.003
36. Lee KH, Kim JY, Kim WK, et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci. 2011;56(2):441-8. DOI:10.1007/s10620-010-1299-x
37. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):84-90 (in Russian)]. DOI:10.17116/terarkh201789284-90
38. Андреев Д.Н., Маев И.В., Дичева Д.Т., и др. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, et al. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):27-32 (in Russian)]. DOI:10.26442/terarkh201890827-32
39. Дичева Д.Т., Андреев Д.Н., Парцваниа-Виноградова Е.В., Маев И.В. Оценка эффективности и безопасности применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori. Пилотное исследование. Медицинский Совет. 2018;(3):86-9 [Dicheva DT, Andreev DN, Partsvania-Vinogradova IV, Maev IV. Evaluation of efficacy and safety of rebamipide use in the triple therapy for Helicobacter pylori eradication: a pilot study. Medical Council. 2018;(3):86-9 (in Russian)].
DOI:10.21518/2079-701X-2018-3-86-89
40. Hahm KB, Lee KJ, Kim YS, et al. Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. Dig Dis Sci. 1998;43(9 Suppl.):192S-7S.
41. Kim JS, Kim JM, Jung HC, Song IS. The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins. Aliment Pharmacol Ther. 2003;18(Suppl. 1):45-54. DOI:10.1046/j.1365-2036.18.s1.1.x
42. Han BG, Kim HS, Rhee KH, et al. Effects of rebamipide on gastric cell damage by Helicobacter pylori-stimulated human neutrophils. Pharmacol Res. 1995;32(4):201-7. DOI:10.1016/s1043-6618(05)80023-4
43. Choi KW, Lee YC, Chung IS, et al. Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage. Dig Dis Sci. 2002;47(2):283-91. DOI:10.1023/a:1013753602149
44. GLOBOCAN 2022: estimated cancer incidence, mortality and prevalence worldwide and Korea in 2022. Available at: 410-korea-republic-of-fact-sheet.pdf. Accessed: 15.03.2024.
45. Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. DOI:10.1159/000495288
46. Shin WG, Kim SJ, Choi MH, et al. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc. 2012;75(4):739-47. DOI:10.1016/j.gie.2011.11.004
47. Takayama M, Matsui S, Kawasaki M, et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol. 2013;19(34):5706-12. DOI:10.3748/wjg.v19.i34.5706

________________________________________________

1. Oh JH, Kwon JG, Jung HK, et al; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29-50. DOI:10.5056/jnm19209
2. Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99 (in Russian). DOI:10.22416/1382-4376-2021-31-4-70-99
3. Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian). DOI:10.22416/1382-4376-2022-32-6-72-93
4. Gastrit i duodenit. Klinicheskie rekomendatsii. Available at: https://cr.minzdrav.gov.ru/recomend/708_2. Accessed: 30.09.2024 (in Russian).
5. Yakovenko EP, Agafonova NA, Ivanov AN, et al. The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract. Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(4):88-92 (in Russian). DOI:10.17116/terarkh201688488-92
6. Simanenkov VI, Lutaenko EA, Nikogosyan AA. Clinical and pharmacological characteristics of the use of rebamipide in diseases of the gastrointestinal tract. Literature review. Medical Council. 2016;(19):88-95 (in Russian). DOI:10.21518/2079-701X-2016-19-88-95
7. Simanenkov VI, Tikhonov SV. Rebamipide: New opportunities of gastroenteroprotection. Terapevticheskii Arkhiv (Ter. Arkh.). 2015;87(12):134-7 (in Russian). DOI:10.17116/terarkh20158712134-137
8. Zvyaglova MYu, Knyazev OV, Parfenov AI. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):104-11 (in Russian). DOI:10.26442/00403660.2020.02.000569
9. Trukhan DI, Ivanova DS. Lekarstvennaia bezopasnost' v real'noi klinicheskoi praktike: aktsent na protektornuiu terapiiu. Farmateka. 2022;29(3):72-82 (in Russian). DOI:10.18565/pharmateca.2022.3.72-82
10. Lapina TL, Ivashkin VT. Rebamipide During Chronic Gastritis: H. pylori Eradication Therapy and Restoration of Gastric Mucosa Barrier Function. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):81-7 (in Russian). DOI:10.22416/1382-4376-2023-33-6-81-87
11. Korobeinikova ER, Shkatova EIu. Primenenie rebamipida v kompleksnoi terapii erozivnykh porazhenii gastroduodenal'noi zony lits molodogo vozrasta. Meditsinskii Al'manakh. 2018;52(1):26-30 (in Russian).
12. Sagynbaeva VE, Lazebnik LB. Rebamipid – sovremennyi gastrotsitoprotektor pri erozivno-iazvennykh porazheniiakh verkhnikh otdelov zheludochno-kishechnogo trakta: rezul'taty issledovaniia. Terapiia. 2019;(8):173-83 (in Russian). DOI:10.18565/therapy.2019.8.173–183
13. Chorbinskaia SA, Kudriavtseva NA, Stepanova II, et al. NPVP-indutsirovannoe porazhenie zheludochno-kishechnogo trakta. Novye vozmozhnosti gastro- i enteroprotektsii. Kremlevskaia meditsina. Klinicheskii vestnik. 2019;(4):98-104 (in Russian).
14. Meshcheriakova GM, Kopylova DV, Vatutina VS. Opyt primeneniia rebamipida v lechenii postluchevogo kolita. Koloproktologiia. 2019;18(S3):87 (in Russian).
15. Tarasova LV, Bashkova IB, Busalaeva EI. Nsaids-associated risks in patients with rheumatological diseases: analysis of medical prescriptions. Eksperimental'naia i Klinicheskaia Gastroenterologiia. 2019;9(169):11-6 (in Russian). DOI:10.31146/1682-8658-ecg-169-9-11-16
16. Bakulina NV, Tikhonov SV, Okovityi SV, et al. Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(12):1431-7 (in Russian). DOI:10.26442/00403660.2022.12.202000
17. Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. DOI:10.1007/s10620-017-4871-9
18. Lain L. Approaches to nonsteroidal anti-inflammatory drug use in high-risk patient. Gastroenterology. 2001;120(3):594-606. DOI:10.1053/gast.2001.21907
19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-7. DOI:10.1136/bmj.321.7270.1183
20. Cha JM, Kim M, Jo HH, et al. Real-World Risk of Gastrointestinal Bleeding for Direct Oral Anticoagulants and Warfarin Users: A Distributed Network Analysis Using a Common Data Model. Gut Liver. 2024;18(5):814-23. DOI:10.5009/gnl230406
21. Cho KM, Park SY, Chung JO, et al. Risk factors for small bowel bleeding in chronic nonsteroidal anti-inflammatory drug users. J Dig Dis. 2015;16(9):499-504.
DOI:10.1111/1751-2980.12269
22. Kim JE, Lee YC, Kim TS, et al. Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors. Gut Liver. 2024;18(6):1026-36. DOI:10.5009/gnl230372
23. Kim TJ, Kim ER, Hong SN, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696. DOI:10.1038/s41598-019-48173-6
24. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391-8.
DOI:10.7326/0003-4819-149-6-200809160-00005
25. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120-8. DOI:10.1001/jama.2009.722
26. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. DOI:10.1371/journal.pone.0216750
27. Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014;8(4):371-9. DOI:10.5009/gnl.2014.8.4.371
28. Gweon TG, Park JH, Kim BW, et al; Incheon and Western Kyonggi Gastrointestinal Study. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. DOI:10.5009/gnl17078
29. Parfenov AI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):25-31 (in Russian). DOI:10.26442/00403660.2019.02.000123
30. Parfenov AI, Belostotsky NI, Dbar SR, et al. Enteropathy with disorder of membrane digestion. Effektivnaia Farmakoterapiia. 2018;(16):20-7 (in Russian).
31. Baulo EV, Belostotsky NI, Akhmadullina OV, et al. The effect of the FODMAP and rebamipid diet on the activity of disaccharidases in patients with enteropathy with impaired membrane digestion. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(2):140-4 (in Russian). DOI:10.26442/00403660.2023.2.202057
32. Statsenko ME, Turkina SV, Tyshchenko IA, et al. Evaluation of the efficacy of rebamipide in functional dyspepsia and irritable bowel syndrome treatment. Experimental and Clinical Gastroenterology. 2022;(9):74-81 (in Russian). DOI:10.31146/1682-8658-ecg-205-9-74-81
33. Song JH, Han YM, Kim WH, et al. Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants. Free Radic Res. 2016;50(10):1071-9. DOI:10.1080/10715762.2016.1181262
34. Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-6. DOI:10.5009/gnl15537
35. Kang DW, Noh YN, Hwang WC, et al. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells. Biochem Pharmacol. 2016;113:36-44. DOI:10.1016/j.bcp.2016.06.003
36. Lee KH, Kim JY, Kim WK, et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci. 2011;56(2):441-8. DOI:10.1007/s10620-010-1299-x
37. Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):84-90 (in Russian). DOI:10.17116/terarkh201789284-90
38. Andreev DN, Maev IV, Dicheva DT, et al. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):27-32 (in Russian). DOI:10.26442/terarkh201890827-32
39. Dicheva DT, Andreev DN, Partsvania-Vinogradova IV, Maev IV. Evaluation of efficacy and safety of rebamipide use in the triple therapy for Helicobacter pylori eradication: a pilot study. Medical Council. 2018;(3):86-9 (in Russian). DOI:10.21518/2079-701X-2018-3-86-89
40. Hahm KB, Lee KJ, Kim YS, et al. Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. Dig Dis Sci. 1998;43(9 Suppl.):192S-7S.
41. Kim JS, Kim JM, Jung HC, Song IS. The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins. Aliment Pharmacol Ther. 2003;18(Suppl. 1):45-54. DOI:10.1046/j.1365-2036.18.s1.1.x
42. Han BG, Kim HS, Rhee KH, et al. Effects of rebamipide on gastric cell damage by Helicobacter pylori-stimulated human neutrophils. Pharmacol Res. 1995;32(4):201-7. DOI:10.1016/s1043-6618(05)80023-4
43. Choi KW, Lee YC, Chung IS, et al. Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage. Dig Dis Sci. 2002;47(2):283-91. DOI:10.1023/a:1013753602149
44. GLOBOCAN 2022: estimated cancer incidence, mortality and prevalence worldwide and Korea in 2022. Available at: 410-korea-republic-of-fact-sheet.pdf. Accessed: 15.03.2024.
45. Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. DOI:10.1159/000495288
46. Shin WG, Kim SJ, Choi MH, et al. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc. 2012;75(4):739-47. DOI:10.1016/j.gie.2011.11.004
47. Takayama M, Matsui S, Kawasaki M, et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol. 2013;19(34):5706-12. DOI:10.3748/wjg.v19.i34.5706

Н.В. Бакулина, В.А. Пономаренко*, И.Г. Бакулин

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
*ponomarenkotori@mail.ru

________________________________________________

Natalia V. Bakulina, Viktoriia A. Ponomarenko*, Igor G. Bakulin

Mechnikov North-Western State Medical University, Saint Petersburg, Russia
*ponomarenkotori@mail.ru